Godavari Biorefineries rises on incorporating wholly owned step down subsidiary in USA
Godavari Biorefineries is currently trading at Rs. 274.40, down by 1.85 points or 0.68% from its previous closing of Rs. 272.55 on the BSE.
The scrip opened at Rs. 278.00 and has touched a high and low of Rs. 278.00 and Rs. 270.95 respectively. So far 1337 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 355.70 on 18-Dec-2024 and a 52 week low of Rs. 145.20 on 28-Mar-2025.
Last one week high and low of the scrip stood at Rs. 280.80 and Rs. 248.45 respectively. The current market cap of the company is Rs. 1389.43 crore.
The promoters holding in the company stood at 63.31%, while Institutions and Non-Institutions held 12.58% and 24.12% respectively.
Godavari Biorefineries has incorporated Sathgen Therapeutics LLC, a wholly owned step down subsidiary based in Princeton, New Jersey, USA. This strategic expansion strengthens the company’s clinical stage biotechnology presence in the United States, with a primary focus on global out-licensing of intellectual property and to build the network to accelerate the drug-development programme.
Sathgen Therapeutics has also formed a Scientific Advisory Board (SAB) to guide its clinical-development and translational-research strategy. The SAB includes Razelle Kurzrock, an internationally known authority in precision oncology, immunotherapy, and early-phase clinical trials, and Massimo Cristofanilli, a leading global expert in metastatic breast cancer and cancer biology.
